RxDoctor Payments DataLook up a doctor →

James Bicksel, MD

Neurology · Mc Lean, VANPI 1265424147

Payments from drug & device makers

$1,047,271in general payments, 2019–2025

Across 850 payments — averaging $1232.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$566K
  • Biogen$465K
  • Teva Pharmaceuticals USA, Inc.$4K
  • AbbVie$3K
  • Impel Pharmaceuticals Inc.$753
  • Supernus Pharmaceuticals, Inc.$733
  • plus $7K from 45 others
$211in research payments, 2019–2025

Across 2 payments — averaging $105.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$211

What the payments were for

  • Food & beverage$16,63599%
  • Education$1611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,047,271 in reported general payments places this provider in the 95th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$271,547
Medicare patients
507
Services billed
26,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4614$276,656
NuplazidPimavanserin Tartrate17$93,257
XywavSodium,calcium,mag,pot Oxybate11$89,017
RytaryCarbidopa/Levodopa55$72,755
Galantamine ErGalantamine Hbr359$40,345
Rivastigmine112$35,722
Memantine Hcl ErMemantine Hcl203$29,146
Galantamine Hbr58$6,492
Memantine Hcl163$5,822
Bupropion XlBupropion Hcl152$5,705
Donepezil Hcl251$4,357
Duloxetine Hcl92$3,791
Rasagiline Mesylate18$3,641
Sertraline Hcl302$3,576
Gabapentin141$3,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$262$93,25717 claims
Amneal Pharmaceuticals LLCRytary$273$72,75555 claims
Almatica Pharma LLCSertraline Hcl$18$3,576302 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 neurology providers in Virginia.

Other neurology in Mc Lean

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →